|
ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor
|
5R00CA158065-05
|
$249,000
|
|
RINK, LORI
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
ZIP4 is a Novel Molecular Target in Human Pancreatic Cancer
|
7R01CA186338-02
|
$347,191
|
|
LI, MIN
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
|
Zinc Chemoprevention of Arsenic Co-Carcinogenesis
|
5R01CA182969-03
|
$314,363
|
|
HUDSON, LAURIE
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
|
Yale SPORE in Skin Cancer
|
4P50CA121974-10
|
$2,161,999
|
|
HALABAN, RUTH
|
YALE UNIVERSITY
|
|
Yale Comprehensive Cancer Center Support Grant
|
2P30CA016359-34
|
$2,531,005
|
$50,620
|
LYNCH, THOMAS
|
YALE UNIVERSITY
|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-34S1
|
$75,000
|
$1,500
|
Lynch, Thomas
|
YALE UNIVERSITY
|
|
Yale Cancer Center NCTN
|
5U10CA180826-03
|
$551,500
|
$27,575
|
HOCHSTER, HOWARD
|
YALE UNIVERSITY
|
|
XLF in double-strand break repair and chemo/radiosensitization
|
4R01CA166264-04
|
$307,872
|
|
POVIRK, LAWRENCE
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
WUMC Cancer and Leukemia Group B
|
5U10CA077440-16
|
$320,126
|
$25,610
|
BARTLETT, NANCY
|
WASHINGTON UNIVERSITY
|
|
Workshop on Methods in Supportive Oncology Research
|
5R25CA181000-03
|
$267,904
|
|
TEMEL, JENNIFER
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Wnt Signaling and Secreted Frizzled-Related Proteins
|
ZIA BC 010251
|
$318,862
|
$63,772
|
Rubin, Jeffrey
|
CCR (NCI)
|
|
Winship Cancer Institute, National Clinical Trials Network Lead Academic Particip
|
5U10CA180864-03
|
$542,807
|
$20,355
|
RAMALINGAM, SURESH
|
EMORY UNIVERSITY
|
|
Whole Genome Sequencing to Discover Familial Myeloma Risk Genes
|
4R01CA167824-05
|
$494,158
|
|
LIPKIN, STEVEN
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
WESTERN ONCOLOGY RESEARCH CONSORTIUM
|
5U10CA045377-27
|
$589,569
|
$5,896
|
Conlin, Alison
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
Weight Management Counseling in Medical Schools: A Randomized Controlled Trial
|
1R01CA194787-01A1
|
$836,820
|
|
OCKENE, JUDITH
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
Web App Technology for Boys and Parents: Improving HPV Vaccine Uptake
|
1R01CA210125-01A1
|
$684,852
|
|
WOODALL, W
|
KLEIN BUENDEL, INC.
|
|
Washington University/ Siteman Cancer Center Lead Academic Site
|
5U10CA180833-03
|
$1,649,280
|
|
BARTLETT, NANCY
|
WASHINGTON UNIVERSITY
|
|
Wake Forest NCORP Research Base
|
5UG1CA189824-03
|
$2,896,475
|
|
LESSER, GLENN
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
VPAC1 Recpetor-Targeted PET Imaging of Prostate Cancer
|
4R01CA157372-05
|
$490,625
|
|
THAKUR, MATHEW
|
THOMAS JEFFERSON UNIVERSITY
|
|
VIRUS DISCOVERY AND CHARACTERIZATION IN LARGE-SCALE CANCER SEQUENCING DATA
|
5R01CA178383-03
|
$255,216
|
|
DING, LI
|
WASHINGTON UNIVERSITY
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-29
|
$612,504
|
$6,125
|
Nichols, Craig
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Viral Oncology Training Grant
|
5T32CA009111-38
|
$378,220
|
|
CULLEN, BRYAN
|
DUKE UNIVERSITY
|
|
VHL tumor suppressor gene and the initiation of renal cell carcinoma
|
3R01CA109860-09S1
|
$88,962
|
$88,962
|
HSU, TIEN
|
BOSTON MEDICAL CENTER
|
|
VHL tumor suppressor gene and the initiation of renal cell carcinoma
|
5R01CA109860-09
|
$308,789
|
$308,789
|
HSU, TIEN
|
BOSTON MEDICAL CENTER
|
|
Veterans Administration hospitalization database, Patient Treatment File, and Out
|
ZIA CP010126-00580
|
$52,897
|
$5,290
|
McGlynn, Katherine
|
DCEG (NCI)
|
|
Vesicular stomatitis VSVrp30 selectively destroys human metastatic melanoma
|
4R01CA161048-05
|
$345,488
|
|
VAN DEN POL, ANTHONY
|
YALE UNIVERSITY
|
|
Vesicular Stomatitis Virus (VSV) Replication in Malignant Cells
|
5R01CA194404-02
|
$332,363
|
|
BARBER, GLEN
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Vermont Breast Cancer Molecular Characterization Laboratory
|
5U01CA196383-02
|
$63,612
|
|
STEIN, JANET
|
UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
|
|
VEGF Signaling in Mammary Tumorigenesis
|
4R01CA168464-05
|
$347,563
|
|
MERCURIO, ARTHUR
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
VCU Minority-Based Community Clinical Oncology Program
|
3U10CA052784-23S1
|
$125,000
|
$1,250
|
Hackney, Mary
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
VCU Minority-Based Community Clinical Oncology Program
|
5U10CA052784-23
|
$431,709
|
$4,317
|
Hackney, Mary
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
Vascular mechanisms regulating breast cancer brain metastasis
|
4R01CA170140-05
|
$357,419
|
|
ELICEIRI, BRIAN
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Vascular communication in metastatic brain colonization
|
5R01CA184594-03
|
$321,625
|
|
KLEMKE, RICHARD
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Varicella virus antigens in glioma etiology and survival
|
5U01CA182371-03
|
$509,396
|
|
WIEMELS, JOSEPH
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Vangl Dependent PCP Signaling Mediates EMT Induced Cell Invasiveness
|
1F31CA210467-01
|
$38,128
|
|
VANDERVORST, KACEY
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
Vanderbilt Training Program in Molecular and Genetic Epidemiology of Cancer
|
5R25CA160056-06
|
$510,371
|
|
SHU, XIAO-OU
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Vanderbilt Network Lead Academic Participating Site for the NCTN
|
5U10CA180847-03
|
$9,808
|
$490
|
BERLIN, JORDAN
|
VANDERBILT UNIVERSITY
|
|
Validation of the Pre-BCR Signaling Complex in pre-B ALL Cell Model by Two-Color Single Particle Tracking and Peptidomimetic Inhibition
|
5F31CA192848-02
|
$30,343
|
|
ERASMUS, MICHAEL
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
|
Validation of Quantitative 11C-Erlotinib PET for Imaging EGFR-Mutant Lung Cancer
|
5R01CA195493-02
|
$257,699
|
|
MORRIS, EVAN
|
YALE UNIVERSITY
|
|
Validation of pancreatic cancer biomarkers in large prospective cohorts
|
5R01CA196286-02
|
$505,275
|
|
LOKSHIN, ANNA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Validation of Methylated Vimentin as a Diagnostic Test for Barrett's Esophagus
|
1UH2CA205105-01
|
$346,395
|
|
WILLIS, JOSEPH
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Validation of circulating tumor DNA assays for detection of metastatic melanoma
|
1UH2CA206124-01
|
$211,875
|
|
POLSKY, DAVID
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
Validation and Development of WEE1 as a therapeutic target in AML
|
4R01CA172385-04
|
$316,213
|
|
PORTER, CHRISTOPHER
|
UNIVERSITY OF COLORADO DENVER
|
|
Validating Technology To Optimize Antibody Affinity For Targeting Therapeutics
|
5R33CA177333-03
|
$76,654
|
|
FEDERSPIEL, MARK
|
MAYO CLINIC ROCHESTER
|
|
Validating Rapid Microfluidic Isolation of Personalized Aptamers for Monitoring Minimal Residual Disease in Multiple Myeloma
|
1R33CA196470-01A1
|
$394,518
|
|
LIN, QIAO
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
UW Radiological Sciences Training Program
|
5T32CA009206-38
|
$391,691
|
|
HALL, TIMOTHY
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10
|
5U10CA180870-03
|
$645,976
|
$16,149
|
GERBER, DAVID
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)
|
5U10CA180858-03
|
$1,192,600
|
$29,815
|
ENG, CATHY
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Using zebrafish to study the role of six1a/b and microRNA-30a in rhabdomyosarcoma (RMS) initiation and progression
|
1R21CA201809-01A1
|
$169,106
|
|
FORD, HEIDE
|
UNIVERSITY OF COLORADO DENVER
|
|
Using Text Messaging to Increase HPV Vaccination among Young Sexual Minority Men
|
1R21CA208329-01
|
$172,938
|
|
GEREND, MARY
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
Total relevant funding to Kidney Cancer for this search: $55,343,109
|